A cell-permeable and blood-brain barrier-permeant aminosalicylic acid compound that selectively disrupts nNOS and PSD-95 interaction uponnMDAR activation both in primary murine cortical neurons (0.8- and 2.8-fold increase from basal level with or without 30min 10uM ZL006 pretreatment) in vitro and in mice (0.4- and 1.9-fold increase from basal level with or without inhibitor pretreatment 15min before ischemia; 1.5mg/kg i.v.) in vivo without affecting nNOS activity or non-nNOS-mediated nMDAR EPSCs (excitatory postsynaptic currents). Effectively reduce ischemia-caused brain tissue damage in both mice and rats when applied 1h after blood reperfusion following ishemia (60% and 50% reduction of infarction, respectively; 1.5mg/kg i.v.).